XGene Regulatory Intelligence Platform
Connect enforcement signals to quality systems, services, expert commentary, and implementation resources.
The helper lipid is the least-discussed component of the 4-component ionizable LNP formulation, and that silence is a CMC problem. When a reviewer opens your 3.2.P.2 pharmaceutical development section and asks why DSPC was
View details →
Only about 8 to 12 percent of FDA 483 observations result in a Warning Letter — but the companies that receive Warning Letters almost always had the opportunity to prevent them, because the patterns
View details → Three FDA-approved LNP drug products — Onpattro, Comirnaty, and Spikevax — have publicly documented ionizable lipid drug substance packages with complete 3.2.S sections, ICH Q7 GMP synthesis histories, and impurity profiles qualified under ICH
View details →
Reliance Life Sciences Private Limited, a Navi Mumbai, India-based sterile injectable manufacturer, has recalled four sterile oncology injectable products — Pemetrexed for Injection (100 mg and 500 mg single-dose vials), Bortezomib for Injection (3.5
View details → Cipla USA, Inc. has recalled three strengths of Cinacalcet Hydrochloride Tablets (30 mg, 60 mg, and 90 mg, manufactured by Cipla Ltd. at its Patalganga, India facility) under a Class II classification confirmed by
View details → Asclemed USA, Inc. has recalled Accucaine, a lidocaine hydrochloride injection kit (1%, 10 mg/mL, 5 mL single-dose ampules) distributed by Enovachem Pharmaceuticals of Torrance, California, under a Class II classification confirmed by FDA on
View details → Blaine Labs Inc, a Santa Fe Springs, California manufacturer, has recalled Revitaderm Wound Care Gel (benzalkonium chloride 0.1%, 1.0 fl. oz. bottles) under a Class I classification confirmed by FDA on July 16, 2026.
View details →
FDA's Pharmaceutical Quality–CMC structured data program has moved well past the pilot stage — the Stage 2 FHIR Implementation Guide cleared HL7 balloting in early 2025 and is now in active build toward a
View details → FDA Warning Letters to drug manufacturers rose roughly 50 to 59 percent year-over-year in FY2025 — and data integrity findings now appear in roughly 15 percent of all FY2025 Warning Letters, climbing to nearly
View details →
Nitrosamine impurities defined a decade of pharmaceutical recalls and regulatory interventions beginning in 2018. The regulatory response — FDA and EMA directives requiring industry-wide risk assessments for all marketed products — created a CMC
View details → The back room during an FDA inspection is where the outcome is actually determined — the front room is where FDA asks the questions, but the back room is where your team decides what
View details → ICH Q3D established a risk-based framework for elemental impurity control that allows most pharmaceutical programs to avoid routine elemental testing if the risk assessment demonstrates that elemental impurity levels are well below the permitted
View details → FDA Warning Letters are the most detailed, most current, and most underutilized source of CMC and GMP competitive intelligence available to pharmaceutical companies — and the organizations that systematically mine this public database are
View details → ICH Q3C is one of the most frequently cited guidance documents in CDER chemistry deficiency letters, and most CMC teams believe they have implemented it correctly because they know the Class 1, 2, and
View details →
Across hundreds of FDA Warning Letters issued to pharmaceutical manufacturers over the past five years, five quality system deficiency patterns appear with such regularity that they constitute a predictive model for where the next
View details →
Scale-up from kilogram to metric-ton synthesis is not a linear amplification. It is a process re-development exercise governed by physical chemistry — heat transfer coefficients that drop by a factor of 5–10 between a
View details → Most pharmaceutical manufacturers have a process validation Stage 3 Continued Process Verification program on paper — and most of those programs are generating data that no one is analyzing, producing control charts that no
View details → There are two moments in LNP manufacturing where the drug product is made. The one that actually determines the physical attributes of the particles you will release into patients is the moment the ethanol
View details →